| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
126,890,000 |
| Market
Cap: |
1.15(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$9.02 - $9.1 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers where there is an unmet medical need. Co. has one commercially approved product, VONJO™ (pacritinib), which has received approval in the U.S. by the U.S. Food and Drug Administration for the treatment of adult patients with intermediate or primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
5,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$27,500 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
9,922,851 |
| Total Sell Value |
$0 |
$0 |
$0 |
$60,660,378 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
29 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Plunkett Matthew |
EVP, Corporate Development |
• – – |
2013-03-21 |
4 |
A |
$0.00 |
$0 |
D/D |
296,705 |
396,705 |
|
- |
|
| Benner Steven E |
EVP, Chief Medical Officer |
• – – |
2013-03-21 |
4 |
A |
$0.00 |
$0 |
D/D |
296,705 |
363,371 |
|
- |
|
| Bianco James A |
President and CEO |
• • – |
2013-03-21 |
4 |
A |
$0.00 |
$0 |
D/D |
989,017 |
1,802,014 |
|
- |
|
| Bianco James A |
President and CEO |
• • – |
2013-03-21 |
4 |
D |
$0.00 |
$0 |
D/D |
(168,562) |
812,997 |
|
- |
|
| Tuckson Reed Vaughn |
Director |
– • – |
2013-03-21 |
4 |
A |
$0.00 |
$0 |
D/D |
109,891 |
303,705 |
|
- |
|
| Tuckson Reed Vaughn |
Director |
– • – |
2013-03-21 |
4 |
D |
$0.00 |
$0 |
D/D |
(28,093) |
193,814 |
|
- |
|
| Telling Fred |
Director |
– • – |
2013-03-21 |
4 |
A |
$0.00 |
$0 |
D/D |
109,891 |
305,106 |
|
- |
|
| Telling Fred |
Director |
– • – |
2013-03-21 |
4 |
D |
$0.00 |
$0 |
D/D |
(28,093) |
195,215 |
|
- |
|
| Mundinger Mary Oneil |
Director |
– • – |
2013-03-21 |
4 |
A |
$0.00 |
$0 |
D/D |
109,891 |
258,378 |
|
- |
|
| Mundinger Mary Oneil |
Director |
– • – |
2013-03-21 |
4 |
D |
$0.00 |
$0 |
D/D |
(28,093) |
148,487 |
|
- |
|
| Love Richard L |
Director |
– • – |
2013-03-21 |
4 |
A |
$0.00 |
$0 |
D/D |
109,891 |
345,308 |
|
- |
|
| Love Richard L |
Director |
– • – |
2013-03-21 |
4 |
D |
$0.00 |
$0 |
D/D |
(28,093) |
235,417 |
|
- |
|
| Gregorian Vartan |
Director |
– • – |
2013-03-21 |
4 |
A |
$0.00 |
$0 |
D/D |
109,891 |
317,980 |
|
- |
|
| Gregorian Vartan |
Director |
– • – |
2013-03-21 |
4 |
D |
$0.00 |
$0 |
D/D |
(28,093) |
208,089 |
|
- |
|
| Singer Jack W |
EVP, Global Medical Affairs |
• • – |
2013-03-11 |
4 |
S |
$1.28 |
$16,640 |
D/D |
(13,000) |
482,504 |
|
- |
|
| Mundinger Mary Oneil |
Director |
– • – |
2013-03-08 |
4 |
S |
$1.28 |
$48,075 |
D/D |
(37,500) |
176,580 |
|
- |
|
| Bianco Louis A |
EVP, Finance & Administration |
• – – |
2013-03-08 |
4 |
S |
$1.28 |
$43,274 |
D/D |
(33,712) |
408,879 |
|
- |
|
| Nudelman Phillip M Phd |
Director |
– • – |
2013-03-08 |
4 |
S |
$1.28 |
$133,533 |
D/D |
(103,900) |
148,415 |
|
- |
|
| Mundinger Mary Oneil |
Director |
– • – |
2013-03-07 |
4 |
S |
$1.27 |
$47,626 |
D/D |
(37,500) |
214,080 |
|
- |
|
| Nudelman Phillip M Phd |
Director |
– • – |
2013-03-07 |
4 |
S |
$1.30 |
$60,057 |
D/D |
(46,100) |
252,315 |
|
- |
|
| Benner Steven E |
EVP, Chief Medical Officer |
• – – |
2013-03-06 |
4 |
GA |
$0.00 |
$0 |
I/I |
33,334 |
33,334 |
|
- |
|
| Benner Steven E |
EVP, Chief Medical Officer |
• – – |
2013-03-06 |
4 |
GD |
$0.00 |
$0 |
D/D |
33,334 |
66,666 |
|
- |
|
| Bianco James A |
President and CEO |
• • – |
2013-03-05 |
4 |
S |
$1.26 |
$94,650 |
D/D |
(75,000) |
981,559 |
|
- |
|
| Tuckson Reed Vaughn |
Director |
– • – |
2012-12-03 |
4 |
A |
$0.00 |
$0 |
D/D |
71,429 |
221,907 |
|
- |
|
| Mundinger Mary Oneil |
Director |
– • – |
2012-12-03 |
4 |
A |
$0.00 |
$0 |
D/D |
71,429 |
251,580 |
|
- |
|
742 Records found
|
|
Page 12 of 30 |
|
|
